Israel - English - Ministry of Health

sanofi israel ltd - agalsidase beta - powder for concentrate for solution for infusion - agalsidase beta 35 mg/vial - agalsidase beta - agalsidase beta - fabrazyme is indicated for use as long-term enzyme replacement therapy in patients with a confirmed diagnosis of fabry disease. (alfa - galactosidase a deficiency).

European Union - English - EMA (European Medicines Agency)

sanofi b.v. - agalsidase beta - fabry disease - other alimentary tract and metabolism products, - fabrazyme is indicated for long-term enzyme replacement therapy in patients with a confirmed diagnosis of fabry disease (α-galactosidase-a deficiency).

Canada - English - Health Canada

sanofi genzyme, a division of sanofi-aventis canada inc - agalsidase beta - powder for solution - 5mg - agalsidase beta 5mg - enzymes

Canada - English - Health Canada

sanofi genzyme, a division of sanofi-aventis canada inc - agalsidase beta - powder for solution - 35mg - agalsidase beta 35mg - enzymes

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

genzyme therapeutics ltd - agalsidase beta - powder for solution for infusion - 5mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

genzyme therapeutics ltd - agalsidase beta - powder for solution for infusion - 35mg

Israel - English - Ministry of Health

sanofi - aventis israel ltd - agalsidase beta 5 mg/ml - powder for concentrate for infusion - agalsidase beta - long-term enzyme replacement therapy in patients with a confirmed diagnosis of fabry disease.

Singapore - English - HSA (Health Sciences Authority)

sanofi-aventis singapore pte. ltd. - agalsidase beta - injection, powder, for solution - 37.0mg/35mg vial - agalsidase beta 37.0mg/35mg vial

Singapore - English - HSA (Health Sciences Authority)

sanofi-aventis singapore pte. ltd. - agalsidase beta - injection, powder, for solution - 5.5mg/5mg vial - agalsidase beta 5.5mg/5mg vial

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

genzyme europe b.v., netherlands - agalsidase beta - powder for concentrate for solution for infusion - 5 mg/ml